Investigational Drug Information for UGN-102
✉ Email this page to a colleague
What is the drug development status for UGN-102?
UGN-102 is an investigational drug.
There have been 4 clinical trials for UGN-102.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, and Carcinoma. The leading clinical trial sponsors are UroGen Pharma Ltd. and [disabled in preview].
There are six hundred and forty-three US patents protecting this investigational drug and zero international patents.
Summary for UGN-102
| US Patents | 643 |
| International Patents | 40,365 |
| US Patent Applications | 4,441 |
| WIPO Patent Applications | 2,834 |
| Japanese Patent Applications | 109 |
| Clinical Trial Progress | Phase 2 (2022-02-01) |
| Vendors | 45 |
Recent Clinical Trials for UGN-102
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | UroGen Pharma Ltd. | Phase 3 |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) | UroGen Pharma Ltd. | Phase 3 |
| A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer | UroGen Pharma Ltd. | Phase 3 |
Clinical Trial Summary for UGN-102
Top disease conditions for UGN-102
Top clinical trial sponsors for UGN-102
US Patents for UGN-102
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| UGN-102 | ⤷ Sign Up | Salts of an epidermal growth factor receptor kinase inhibitor | Celgene CAR LLC (Pembroke, BM) | ⤷ Sign Up |
| UGN-102 | ⤷ Sign Up | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Sign Up |
| UGN-102 | ⤷ Sign Up | Pharmaceutical compounds | Cascadian Therapeutics, Inc. (Seattle, WA) | ⤷ Sign Up |
| UGN-102 | ⤷ Sign Up | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (San Diego, CA) | ⤷ Sign Up |
| UGN-102 | ⤷ Sign Up | Method of preparing carboxylic acid functionalized polymers | NEKTAR THERAPEUTICS (San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for UGN-102
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| UGN-102 | Australia | AU2017232930 | 2036-03-16 | ⤷ Sign Up |
| UGN-102 | Canada | CA3017254 | 2036-03-16 | ⤷ Sign Up |
| UGN-102 | European Patent Office | EP3429354 | 2036-03-16 | ⤷ Sign Up |
| UGN-102 | World Intellectual Property Organization (WIPO) | WO2017161165 | 2036-03-16 | ⤷ Sign Up |
| UGN-102 | European Patent Office | EP2896401 | 2032-09-12 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
